Clinical trials: Spinal Column Tumor
Multiple Myeloma
A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)
The purpose of this original study is to determine the recommended phase 2 dose (RP2D) of TAK-079 when administered to participants with NDMM in combination with the backbone treatment regimen.
- Trial name
- NCT03984097
- Testing
- TAK-079, Lenalidomide, Dexamethasone
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Takeda
Lymphoblastic Lymphoma
LBL-2016 for Children or Adolescents in China
The outcomes of children with lymphoblastic lymphoma (LBL) in China in the investigators' previous study were not unexpected. In this study, through further modification treatment protocols and strengthen domestic multicenter…
- Trial name
- NCT02845882
- Testing
- Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, 6-mercaptopurine,Methotrexate, Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine
- Where
- 2 sites in China
- Volunteers
- 150 people
- Sponsor
- Children's Cancer Group, China
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
This randomized phase III trial studies how well imatinib mesylate works in combination with two different chemotherapy regimens in treating patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic…
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia
- Trial name
- NCT03007147
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Calaspargase Pegol, Cyclophosphamide
- Where
- 226 sites in United States, Australia and 17 more
- Volunteers
- 352 people
- Sponsor
- Children's Oncology Group
Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy
PRO-BOOST-LC: Whole-Gland Boost Strategies Versus SBRT Monotherapy in PSMA-Staged Localized and Locally Advanced Prostate Cancer
PRO-BOOST-LC is a prospective, multicenter, randomized phase II/III clinical trial for men with localized or locally advanced prostate cancer without lymph node or distant metastases, confirmed using prostate-specific membrane…
- Conditions
- Prostate Cancer (Adenocarcinoma), Prostate Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors
- Trial name
- PRO-BOOST-LC (NCT07426055)
- Testing
- Stereotactic Body Radiotherapy (SBRT) Monotherapy, External Beam Radiotherapy (EBRT) Backbone, High-Dose-Rate Brachytherapy Boost
- Where
- Poland
- Volunteers
- 1,000 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Multiple Myeloma
A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)
This is a study of pembrolizumab (MK-3475) in combination with lenalidomide and low-dose dexamethasone in participants with refractory or relapsed and refractory Multiple Myeloma (rrMM), and in combination with carfilzomib and…
- Trial name
- NCT02036502
- Testing
- Pembrolizumab, Lenalidomide, Dexamethasone
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC